George T Tsangaris1, Konstantinos Dimas2, Angeliki Malamou1, Angeliki Katsafadou1, Chrissa Papathanasiou3, Dimitrios J Stravopodis4, Constantinos E Vorgias5, Maria Gazouli6, Athanasios K Anagnostopoulos7. 1. Proteomics Research Unit, Biomedical Research Foundation of the Academy of Athens, Athens, Greece. 2. Laboratory of Pharmacology, Faculty of Medicine, University of Thessaly, Larissa, Greece. 3. Hematology/Oncology Unit, First Department of Pediatrics, Aghia Sophia Children's Hospital, University of Athens, Athens, Greece. 4. Department of Cell Biology and Biophysics, Faculty of Biology, School of Sciences, National and Kapodistrian University of Athens, Athens, Greece. 5. Department of Biochemistry and Molecular Biology, National and Kapodistrian University of Athens, Athens, Greece. 6. Department of Molecular Biology, Medical School, National and Kapodistrian University of Athens, Athens, Greece. 7. Proteomics Research Unit, Biomedical Research Foundation of the Academy of Athens, Athens, Greece atanagnost@bioacademy.gr.
Abstract
BACKGROUND/AIM: Medulloblastoma (MBL), an archetypal primitive neuroectodermal tumor of the cerebellum, is the most common pediatric central nervous system malignancy representing approximately 20% of all childhood brain tumors. Herein, we report on a new xenotransplantable tumor cell line, derived from a 6-year-old female patient with cerebellar medulloblastoma, and the completele proteome molecular characterization of subsequent tumors from MBL xenotrasplanted mice. MATERIALS AND METHODS: Tumors were grown in nude mice as subcutaneous xenografts (MBLX) composed of small round cells with hyperchromatic nuclei and scant cytoplasm. Tumor specimen were extracted from animals upon their sacrifice and their molecular proteomic content was analyzed by 2-DE coupled to MALDI-TOF MS analysis. RESULTS: Altogether 350 single-gene products were identified through the current approach, reported as the MBLX database. CONCLUSION: This new xenotransplantable tumor model, offers the scientific community valuable insight on the validity of xenografts altogether, while providing the means for a novel experimental model towards the study of human MBL. Copyright
BACKGROUND/AIM: Medulloblastoma (MBL), an archetypal primitive neuroectodermal tumor of the cerebellum, is the most common pediatric central nervous system malignancy representing approximately 20% of all childhood brain tumors. Herein, we report on a new xenotransplantable tumor cell line, derived from a 6-year-old female patient with cerebellar medulloblastoma, and the completele proteome molecular characterization of subsequent tumors from MBL xenotrasplanted mice. MATERIALS AND METHODS:Tumors were grown in nude mice as subcutaneous xenografts (MBLX) composed of small round cells with hyperchromatic nuclei and scant cytoplasm. Tumor specimen were extracted from animals upon their sacrifice and their molecular proteomic content was analyzed by 2-DE coupled to MALDI-TOF MS analysis. RESULTS: Altogether 350 single-gene products were identified through the current approach, reported as the MBLX database. CONCLUSION: This new xenotransplantable tumor model, offers the scientific community valuable insight on the validity of xenografts altogether, while providing the means for a novel experimental model towards the study of humanMBL. Copyright
Authors: Dennis Wang; Nhu-An Pham; Jiefei Tong; Shingo Sakashita; Ghassan Allo; Lucia Kim; Naoki Yanagawa; Vibha Raghavan; Yuhong Wei; Christine To; Quang M Trinh; Maud H W Starmans; Michelle A Chan-Seng-Yue; Dianne Chadwick; Lei Li; Chang-Qi Zhu; Ni Liu; Ming Li; Sharon Lee; Vladimir Ignatchenko; Dan Strumpf; Paul Taylor; Nadeem Moghal; Geoffrey Liu; Paul C Boutros; Thomas Kislinger; Melania Pintilie; Igor Jurisica; Frances A Shepherd; John D McPherson; Lakshmi Muthuswamy; Michael F Moran; Ming-Sound Tsao Journal: Int J Cancer Date: 2016-11-07 Impact factor: 7.396
Authors: Marcin Imielinski; Alice H Berger; Peter S Hammerman; Bryan Hernandez; Trevor J Pugh; Eran Hodis; Jeonghee Cho; James Suh; Marzia Capelletti; Andrey Sivachenko; Carrie Sougnez; Daniel Auclair; Michael S Lawrence; Petar Stojanov; Kristian Cibulskis; Kyusam Choi; Luc de Waal; Tanaz Sharifnia; Angela Brooks; Heidi Greulich; Shantanu Banerji; Thomas Zander; Danila Seidel; Frauke Leenders; Sascha Ansén; Corinna Ludwig; Walburga Engel-Riedel; Erich Stoelben; Jürgen Wolf; Chandra Goparju; Kristin Thompson; Wendy Winckler; David Kwiatkowski; Bruce E Johnson; Pasi A Jänne; Vincent A Miller; William Pao; William D Travis; Harvey I Pass; Stacey B Gabriel; Eric S Lander; Roman K Thomas; Levi A Garraway; Gad Getz; Matthew Meyerson Journal: Cell Date: 2012-09-14 Impact factor: 41.582
Authors: David M Ashley; Thomas E Merchant; Douglas Strother; Tianni Zhou; Patricia Duffner; Peter C Burger; Douglas C Miller; Nancy Lyon; Melanie J Bonner; Michael Msall; Allen Buxton; Russell Geyer; Larry E Kun; Lee Coleman; Ian F Pollack Journal: J Clin Oncol Date: 2012-07-30 Impact factor: 44.544
Authors: Francesco Cuccia; Gianluca Mortellaro; Lucia Ognibene; Giuseppe Craparo; Antonio Lo Casto; Giuseppe Ferrera Journal: In Vivo Date: 2020 May-Jun Impact factor: 2.155